Shortened Dual Anticoagulation Therapy After Stent Placement Shows Equal Efficacy with Reduced Bleeding Risk in AFib Patients
核心洞察
The OPTIMA-AF trial demonstrated that one month of dual clot-preventing therapy followed by single anticoagulant treatment was as effective as 12 months of dual therapy in preventing stroke (搜索), heart attack (搜索), and death in AFib patients with coronary stents.
Patients receiving the shortened regimen experienced significantly fewer bleeding complications (4.8% vs 9.5%) compared to the standard year-long dual therapy group.
This is the first study to establish that a one-month dual anticoagulation strategy is both safe and effective for AFib patients after stent placement, potentially transforming clinical practice.
New research presented at the American Heart Association's Scientific Sessions 2025 demonstrates that a simplified one-month dual anticoagulation regimen following coronary stent placement in atrial fibrillation (搜索) patients provides equivalent cardiovascular protection to standard year-long therapy while significantly reducing bleeding complications.
The OPTIMA-AF trial, led by Dr. Yohei Sotomi from the University of Osaka Graduate School of Medicine (搜索), represents the first study to establish that shortened dual antithrombotic therapy can safely replace the current 12-month standard of care in this patient population.
Study Design and Patient Population
The multicenter trial enrolled 1,101 adults with an average age of 75.2 years across 75 hospitals in Japan between October 2019 and September 2024. Participants had atrial fibrillation (搜索) and underwent drug-eluting stent implantation procedures. The study population was predominantly male (79%), with most patients having stable heart disease.
Researchers randomly assigned participants to receive either one month of dual therapy followed by single anticoagulant treatment for the remaining 11 months, or continuous dual therapy for the full 12-month period. The dual therapy regimen included a direct oral anticoagulant (such as dabigatran, rivaroxaban, apixaban, or edoxaban) combined with a P2Y12 (搜索) inhibitor (clopidogrel or prasugrel).
Primary Efficacy and Safety Outcomes
The trial's primary composite endpoint of stroke (搜索), heart attack (搜索), or death occurred in 5.4% of patients in the one-month group compared to 4.5% in the 12-month group, demonstrating non-inferiority of the shortened regimen. This finding suggests the abbreviated approach maintains equivalent cardiovascular protection.
More significantly, the shortened regimen produced a substantial reduction in bleeding complications. Only 4.8% of patients in the one-month group experienced bleeding events compared to 9.5% in the standard 12-month group. According to Dr. Sotomi, most of the bleeding reduction involved less serious bleeds requiring medical attention, which nonetheless affect quality of life and increase healthcare costs through emergency visits and additional testing.
Clinical Implications for AFib Management
"Previous studies confirmed that using two anti-clotting agents instead of three reduced bleeding, however, no study has tested whether the duration of dual therapy could be safely shortened to just one month," Dr. Sotomi explained. "Our study is the first to show that a one-month strategy is both safe and effective, offering real-world benefits for patients and doctors."
The findings address a critical clinical challenge in managing patients with both atrial fibrillation (搜索) and coronary artery disease (搜索) requiring stent placement. Up to one in 10 stent recipients also have AFib, a condition that increases stroke (搜索) risk five-fold and can lead to blood clots, heart failure, and death. Current treatment guidelines require balancing stroke prevention with bleeding risk management, particularly challenging in older adults who comprise the majority of this patient population.
Study Limitations and Future Directions
The research has several important limitations that may affect generalizability. The study was conducted exclusively in Japan, potentially limiting applicability to other populations. Additionally, participants predominantly had stable heart disease, so results may not extend to higher-risk patients with acute coronary syndromes. The study's gender distribution, with only 20% female participants, also limits generalizability to women.
Dr. Sotomi noted that these results may help physicians feel more confident prescribing shorter durations of dual antithrombotic therapy after stenting in selected AFib patients. "By reducing the length of time individuals are exposed to combination therapy, we can lower the risk of bleeding—a serious concern for many older adults—without increasing their risk of stroke (搜索) or heart attack (搜索)," he said.
Growing AFib Burden
The research addresses an increasingly important clinical need. According to American Heart Association 2025 Heart and Stroke (搜索) statistics, an estimated five million adults in the U.S. currently have atrial fibrillation (搜索), with projections indicating more than 12 million Americans will have the condition by 2030.
The findings represent preliminary data from an abstract presentation and require peer-reviewed publication before clinical implementation. However, the results suggest a potential paradigm shift in post-stent anticoagulation management for AFib patients, offering the possibility of maintaining cardiovascular protection while reducing bleeding-related morbidity and healthcare utilization.